BioCryst Pharmaceuticals (NASDAQ:BCRX) Downgraded to Buy Rating by Wall Street Zen

Wall Street Zen downgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a strong-buy rating to a buy rating in a research note released on Saturday.

BCRX has been the topic of several other reports. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. HC Wainwright reiterated a “buy” rating and set a $32.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Needham & Company LLC reduced their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Wedbush decreased their price target on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. began coverage on shares of BioCryst Pharmaceuticals in a report on Monday, July 13th. They set a “neutral” rating and a $12.00 price target on the stock. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.60.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX opened at $9.82 on Friday. The company has a market cap of $2.51 billion, a price-to-earnings ratio of -6.55 and a beta of 0.55. The firm has a 50 day simple moving average of $9.71 and a 200 day simple moving average of $9.05. BioCryst Pharmaceuticals has a one year low of $6.00 and a one year high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The firm had revenue of $218.25 million for the quarter, compared to analysts’ expectations of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The company’s revenue was up 33.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.15 earnings per share. As a group, analysts expect that BioCryst Pharmaceuticals will post -2.25 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of BCRX. Royal Bank of Canada boosted its stake in shares of BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 1,458 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in BioCryst Pharmaceuticals by 6.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock worth $1,019,000 after buying an additional 8,517 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in BioCryst Pharmaceuticals by 49.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock valued at $14,490,000 after buying an additional 640,704 shares during the period. Caxton Associates LLP acquired a new position in BioCryst Pharmaceuticals in the first quarter valued at $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in BioCryst Pharmaceuticals by 11.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock valued at $3,363,000 after buying an additional 47,355 shares during the period. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.